We have signed a collaborative research agreement with Eisai Inc. (CEO: TATSUYUKI YASUNO) regarding periostin splicing variants in the field of cancer.

The purpose of this collaborative research is to clarify the role of periostin splicing variants, which are our therapeutic target, in specific types of cancer.

Due to confidentiality agreements, the details of the contract will not be disclosed, but we will receive research funding from Eisai Inc.